LVTX Live signaler | Maksimer profitt med Getagraph.com

SELG 120097 min ago

@ $1.749

Utstedt: 9 feb 2024 @ 16:59

Avkastning: 77.23%

Forrige signal: feb 8 - 21:16

Forrige signal: Kjøp

Avkastning: 5.05 %

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 22:00):

Stats
Dagens volum	39 170.00
Gjennomsnittsvolum	1.13M
Markedsverdi	81.50M
EPS	$0 ( 2024-04-09 )
Neste inntjeningsdato	( $-0.250 ) 2024-06-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.970
ATR14	$0.0130 (0.42%)

Volum Korrelasjon

Lang: -0.23 (neutral)

Kort: 0.58 (weak)

Signal:(56.537) Neutral

Lava Therapeutics B.V. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Lava Therapeutics B.V. Korrelasjon - Valuta/Råvare

-0.08
( neutral )

-0.05
( neutral )

0.00
( neutral )

0.10
( neutral )

-0.70
( moderate negative )

-0.32
( neutral )

Lava Therapeutics B.V. Økonomi

Annual	2023
Omsetning:	$6.77M
Bruttogevinst:	$3.29M (48.56 %)
EPS:	$-1.570

FY	2023
Omsetning:	$6.77M
Bruttogevinst:	$3.29M (48.56 %)
EPS:	$-1.570

FY	2022
Omsetning:	$19.39M
Bruttogevinst:	$19.39M (100.00 %)
EPS:	$-1.230

FY	2021
Omsetning:	$5.00M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.30

Financial Reports:

No articles found.

Lava Therapeutics B.V.

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.